Assembly Biosciences (ASMB) vs Atea Pharmaceuticals (AVIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 68.7% versus a loss of 3.8%. Over five years, ASMB leads with a -41.3% price change compared with -87.2% for AVIR. Assembly Biosciences is the larger company by market cap ($464.6 million vs $415.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | AVIR |
|---|---|---|
| Share price | $22.82 | $5.19 |
| Market cap | $464.63M | $415.86M |
| 1-day change | -0.57% | +3.49% |
| YTD return | -32.52% | +40.34% |
| 1-year return | -3.81% | +68.69% |
| 5-year return | -41.33% | -87.25% |
| P/E ratio (TTM) | 21.94 | — |
| EPS (TTM) | $1.04 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $6.45 |
| 52-week low | $21.80 | $2.87 |
| Distance from 52-week high | -42.53% | -19.61% |
| Analyst consensus | none | none |
| Avg. price target upside | +127.87% | +81.68% |
| Average volume | 278.07K | 298.38K |
| Shares outstanding | 20.36M | 80.20M |
| Employees | 73 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed ASMB by 72.5 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
ASMB vs AVIR FAQ
Which is bigger, Assembly Biosciences or Atea Pharmaceuticals?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $464.63M compared with $415.86M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, ASMB or AVIR?
AVIR returned +68.69% over the past 12 months, compared with -3.81% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Atea Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.